Clindamycin Phosphate From Teva Parenteral With Clindamycin Phosphate Eq 150mg Base/ml Information for Drugs and Acne

The Ingredients: Clindamycin Phosphate
Dosage Form and Administration: Injectable; Injection
Drug Trade Name: Clindamycin Phosphate
Firm: Teva Parenteral
Strength: EQ 150MG BASE/ML
New Drug Application Type: A
The Drug Application Number:63041
Medicine Product Number: 1
Approval Date: 12/29/1989
Reference Listed Drug: No
Type: DISCN
Applicant Full Name: Teva Parenteral Medicines Inc

FDA Medical Device Registration

Owners or operators of places of business that are involved in the production and distribution of medical devices intended for use in the United States must register annually with the FDA, which is a process known as establishment registration. Congress has authorized FDA to collect an annual establishment registration fee for device establishment registrations. A detailed list of all those establishment types that have to pay the registration fee is available at "Who Must Register, List and Pay the Fee." There are no reductions in annual establishment registration fees for small businesses or any other group. Most establishments that are required to register with the FDA are also required to list the devices made there and the functions of those devices. If a device requires pre-market approval or notification before marketed in the U.S., then the owner/operator should also submit the FDA pre-market submission number. The amendments to the Medical Device User Fee Modernization Act require that after September 30, 2007, all businesses submit registration and listing information electronically. Registration and listing provides the FDA with the location of medical device establishments and the devices manufactured at those establishments. This information augments the ability of the United States to prepare for and respond to public health emergencies.

Drug Abuse Crime Connection

It is easy to see the connection between drug abuse and crime. Drug abuse is criminal in the following ways: drug possession or sales; to drug abuse e.g., stealing to get money for drugs; and a drug abuse lifestyle that predisposes the drug abuser to engage in illegal activity, like associating with other offenders or dealing in illicit markets. Individuals who use illicit drugs are more likely to commit crimes and it is common for individuals who had used drugs or alcohol to commit many offenses, including violent crimes.
After a nationally representative survey of state correctional agencies in 2005, Criminal Justice Drug Abuse Treatment Studies (CJ–DATS) investigators estimated that nearly 8 million adults were involved in the justice system (Taxman, Young, Wiersema, et al., 2007). Almost 5 million individuals are on probation or under parole supervision (Glaze and Bonczar, 2006; Taxman, Young, Wiersema, et al., 2007), with drug law violators accounting for the largest percentage of these parolees. The substance abuse or dependence rates of offenders are more than four times that of the general population (National Institute of Justice, 2003; U.S. Department of Health and Human Services, 2006). In a 2004 survey, the Bureau of Justice Statistics BJS estimated that about 53 percent of state and 45 percent of federal prisoners met Diagnostic and Statistical Manual for Mental Disorders (DSM) criteria for drug abuse or dependence (Mumola and Karberg, 2006). Of those surveyed, 14.8 percent of state and 17.4 percent of federal prisoners reported having drug treatment since admission (Mumola and Karberg, 2006). Juvenile justice systems also report high levels of drug abuse. A survey of juvenile detainees in 2000 found that about 56 percent of the boys and 40 percent of the girls tested positive for drug use at the time of arrest (National Institute of Justice, 2003).
Although there has been an increased interest in providing substance abuse treatment services for criminal justice offenders, in the last decade, only a small percentage of offenders have access to adequate services, especially in jails and community correctional facilities (Taxman, Perdoni and Harrison, 2007). Not only is there a gap in the availability of these services for offenders, but often there are few choices in the types of services provided. Treatment is of insufficient quality and intensity or is not well suited to the needs of offenders and may not yield meaningful reductions in drug use and recidivism. Untreated substance abusing offenders are more likely to relapse to drug abuse and return to criminal behavior than treated offenders. Relapse can bring about re-arrest and re-incarceration, jeopardizing public health and public safety and taxing criminal justice system resources. Treatment offers the best alternative for interrupting the drug abuse/criminal justice cycle for offenders with drug abuse problems.
Drug abuse treatment can be incorporated into criminal justice settings in a variety of ways. These include treatment as a condition of probation; drug courts that blend judicial monitoring and sanctions with treatment; treatment in prison followed by community-based treatment after release; and treatment under parole or probation supervision. Actual drug abuse treatment efficiency can benefit from the cross-agency coordination and collaboration of criminal justice professionals, substance abuse treatment providers and other social service agencies. By working together, the criminal justice and treatment systems can optimize resources to benefit the health, safety and wellbeing of the individuals and communities they serve.